Integrated Filling_Finacial Results for the year 31-03-2026
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indo US Bio-Tech Limited reported standalone revenue from operations of Rs. 11.04 crore for FY26, up from Rs. 10.36 crore in FY25, representing approximately 6.5% revenue growth. However, net profit declined significantly to Rs. 1.31 crore from Rs. 1.63 crore in the prior year, a drop of about 19.3%. The auditors issued an unmodified opinion, meaning no material misstatements were found. However, the auditors' report includes an Emphasis of Matter drawing attention to: (1) pending confirmations not yet received on certain trade receivables, trade payables, unsecured loans, deposits, and advances given to growers; and (2) inability to verify customer details for cash sales to retail customers and farmers. The company reported a negative operating cash flow of Rs. 12.50 crore, primarily due to a significant increase in inventories of Rs. 29.27 crore. There are disputed income tax demands totaling approximately Rs. 207.71 lakh pending at various appellate forums.
While the company maintains revenue growth and profitability, the significant decline in net profit and negative operating cash flow are concerning for investors. The auditors' emphasis on unverified cash sales and pending account confirmations raises some quality-of-earnings concerns. The unmodified audit opinion is positive, but the Emphasis of Matter paragraph warrants investor attention.